Acute Hepatic Porphyria
Rare Disease·MeSH: Coproporphyria, Hereditary
Prevalence
30.0 / 100K
1 drug in development·1 company·2 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| GIVLAARI | ALNYLAM PHARMACEUTICALS, INC. (ALNY) |
Frequently asked questions
How many drugs are in development for Acute Hepatic Porphyria?
BioSniper tracks 1 drug in development for Acute Hepatic Porphyria across 1 company.
How many clinical trials target Acute Hepatic Porphyria?
There are 2 clinical trials targeting Acute Hepatic Porphyria tracked by BioSniper.
What is the prevalence of Acute Hepatic Porphyria?
The estimated prevalence of Acute Hepatic Porphyria is approximately 30.0 per 100,000 population.
Deep-dive into Acute Hepatic Porphyria
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis